Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 15(2): e0229256, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32084204

RESUMO

Cigarette smoke (CS) contains multiple gaseous and particulate materials that can cause lung inflammation, and smoking is the major cause of chronic obstructive pulmonary disease (COPD). We sought to determine the mechanisms of how CS triggers lung inflammation. Nur77, a nuclear hormone receptor belonging to the immediate-early response gene family, controls inflammatory responses, mainly by suppressing the NF-κB signaling pathway. Because it is unknown if Nur77's anti-inflammatory role modulates COPD, we assessed if and how Nur77 expression and activity are altered in CS-induced airway inflammation. In lung tissues and bronchial epithelial cells from COPD patients, we found Nur77 was downregulated. In a murine model of CS-induced airway inflammation, CS promoted lung inflammation and also reduced Nur77 activity in wild type (WT) mice, whereas lungs of Nur77-deficient mice showed exaggerated CS-induced inflammatory responses. Our findings in in vitro studies of human airway epithelial cells complemented those in vivo data in mice, together showing that CS induced threonine-phosphorylation of Nur77, which is known to interfere with its anti-inflammatory functions. In summary, our findings point to Nur77 as an important regulator of CS-induced inflammatory responses and support the potential benefits of Nur77 activation for COPD treatment.


Assuntos
Regulação para Baixo/efeitos dos fármacos , Nicotiana/química , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/genética , Doença Pulmonar Obstrutiva Crônica/genética , Fumaça/efeitos adversos , Animais , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Humanos , Inflamação/genética , Pulmão/patologia , Camundongos , Fosforilação/efeitos dos fármacos , Doença Pulmonar Obstrutiva Crônica/patologia , Treonina/metabolismo
2.
Am J Pathol ; 189(3): 482-491, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30414411

RESUMO

The transcription factor Nur77 belongs to the NR4A subfamily of nuclear hormone receptors. It features an atypical ligand-binding site that precludes canonical ligand binding, leading to the designation orphan nuclear receptor. However, recent studies show that small molecules can interact with the receptor and modulate its activity by inducing a conformational change in the Nur77 ligand-binding site. Nur77 expression and activation are rapidly induced by various physiological and pathologic stimuli. Once expressed, Nur77 initiates transcriptional activity and modulates expression of its target genes. Both in vitro and in vivo evidence shows that Nur77 dampens the immune response to proinflammatory stimuli, such as tumor necrosis factor-α, Toll-like receptor ligands, and oxidized lipids, primarily by suppressing NF-κB signaling. Although studies focusing on Nur77's role in lung pathophysiology are currently incomplete, available data support its involvement in the pathogenesis of lung diseases, including asthma, acute lung injury, and pulmonary fibrosis, and thus suggest a therapeutic potential for Nur77 activation in these diseases. This review addresses the mechanisms that control Nur77 as well as its known roles in inflammation-related lung diseases. Evidence regarding the therapeutic potential of Nur77-targeting molecules will also be presented. Although current knowledge is limited, additional research followed by clinical studies may firmly identify Nur77 as a pharmacologic target for inflammation-related lung diseases.


Assuntos
Pneumopatias/metabolismo , Pulmão/metabolismo , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/metabolismo , Transdução de Sinais , Transcrição Gênica , Animais , Humanos , Inflamação/metabolismo , Inflamação/patologia , Pulmão/patologia , Pneumopatias/patologia , Pneumopatias/terapia , NF-kappa B/biossíntese , Receptores Toll-Like/biossíntese , Fator de Necrose Tumoral alfa/biossíntese
3.
Am J Physiol Heart Circ Physiol ; 313(3): H524-H545, 2017 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-28626075

RESUMO

Sex differences between women and men are often overlooked and underappreciated when studying the cardiovascular system. It has been long assumed that men and women are physiologically similar, and this notion has resulted in women being clinically evaluated and treated for cardiovascular pathophysiological complications as men. Currently, there is increased recognition of fundamental sex differences in cardiovascular function, anatomy, cell signaling, and pathophysiology. The National Institutes of Health have enacted guidelines expressly to gain knowledge about ways the sexes differ in both normal function and diseases at the various research levels (molecular, cellular, tissue, and organ system). Greater understanding of these sex differences will be used to steer future directions in the biomedical sciences and translational and clinical research. This review describes sex-based differences in the physiology and pathophysiology of the vasculature, with a special emphasis on sex steroid receptor (estrogen and androgen receptor) signaling and their potential impact on vascular function in health and diseases (e.g., atherosclerosis, hypertension, peripheral artery disease, abdominal aortic aneurysms, cerebral aneurysms, and stroke).


Assuntos
Androgênios/metabolismo , Doenças Cardiovasculares/metabolismo , Sistema Cardiovascular/metabolismo , Estrogênios/metabolismo , Hormônios Esteroides Gonadais/metabolismo , Animais , Doenças Cardiovasculares/fisiopatologia , Doenças Cardiovasculares/terapia , Sistema Cardiovascular/fisiopatologia , Feminino , Disparidades nos Níveis de Saúde , Disparidades em Assistência à Saúde , Humanos , Masculino , Receptores Androgênicos/metabolismo , Receptores de Estrogênio/metabolismo , Fatores Sexuais , Transdução de Sinais
4.
J Cell Biochem ; 104(4): 1172-80, 2008 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-18247342

RESUMO

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily. TRAIL shows strong cytotoxicity to many cancer cells but minimal cytotoxicity to most normal cells. Interestingly, our recent studies have demonstrated that pretreatment with TRAIL induces acquired resistance to TRAIL (Song et al. 2007 J Biol Chem 282: 319). Acquired TRAIL resistance develops within 1 day and gradually decays within 5 days after TRAIL treatment. In our current study, we examined whether human colorectal carcinoma CX-1 cells with acquired TRAIL resistance are resistant to UV irradiation as well. CX-1 cells were treated with 200 ng/ml TRAIL for 6 h and incubated various times (0.25-5 days) and then challenged to UV irradiation. Unexpectedly, we observed an increase in apoptosis in acquired TRAIL resistant cells after UVC as well as UVB exposure. This was due to an increase in caspase activation which was mediated through cytochrome c release. These results suggest that cells with acquired TRAIL resistance are sensitive to UV irradiation.


Assuntos
Apoptose/efeitos da radiação , Neoplasias Colorretais/terapia , Resistencia a Medicamentos Antineoplásicos , Ligante Indutor de Apoptose Relacionado a TNF/farmacologia , Raios Ultravioleta , Apoptose/efeitos dos fármacos , Caspases/metabolismo , Linhagem Celular Tumoral , Neoplasias Colorretais/patologia , Citocromos c/metabolismo , Humanos , Ligante Indutor de Apoptose Relacionado a TNF/uso terapêutico , Terapia Ultravioleta
5.
J Air Waste Manag Assoc ; 57(12): 1447-51, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18200929

RESUMO

This study investigated the reforming characteristics and optimum operating condition of the high-temperature plasma torch (so called plasmatron) for hydrogen-rich gas (syngas) production. At the optimum condition, the composition of produced syngas was 45.4% hydrogen (H2), 6.9% carbon monoxide (CO), 1.5% carbon dioxide (CO2), and 1.1% acetylene (C2H2). The H2/CO ratio was 6.6, hydrogen yield was 78.8%, and the energy conversion rate was 63.6%. To obtain the optimum operating condition, parametric studies were carried out examining the effects of O2/CH4 ratio, steam/CH4 ratio, and Ni catalyst addition in reactor. When the steam/CH4 ratio was 1.23, the production of hydrogen was maximized and the methane conversion rate was 99.7%. The syngas composition was determined to be 50.4% H2, 5.7% CO, 13.8% CO2, and 1.1% C2H2. The H2/CO ratio was 9.7, hydrogen yield was 93.7%, and the energy conversion rate was 78.8%. Hydrogen production with catalyst was effective, compared with no catalyst.


Assuntos
Temperatura Alta , Hidrogênio/química , Metano/química , Fontes de Energia Bioelétrica , Catálise , Conservação de Recursos Energéticos , Eliminação de Resíduos , Vapor , Volatilização
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA